Organix, Inc., part of Symeres BV, is a company headquartered in Woburn, MA. The firm provides organic synthesis services. It was founded in 1986 by Raj K. Razdan, Howard Sard and Peter Meltzer. Anu Mahadevan is the CEO, in this role since 1997. Symeres BV acquired Organix, Inc. on April 26, 2022.\nThe company says this about itself: Organix is a Contract Research Organization (CRO) founded in 1986, based in Woburn (US) just outside of Boston. It is a fast-growing company with c.45 employees that serves scientists in biopharma firms all over the world, providing high-quality organic chemistry services, primarily in the areas of lipids and small molecules. The company is owned and led by Dr. Anu Mahadevan, CEO and Dr. Paul Blundell, President.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. They are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology.

Alla Chem LLC is a company headquartered in Hallandale Beach, FL, involved in pharmaceutical preparations. It was founded in 2004.

CIS Bio International SA engages in the distribution of radiopharmaceuticals for diagnosis and therapy. The company is headquartered in Saclay, France.

nLife Therapeutics, S.L., a Granada, Spain-based company that develops innovative tratments for CNS diseases. The company intends to use the funds to advance clinical trials for its treatments. nLife Therapeutics is working on next generation targeted nucleic acids products. Its technology delivers conjugated nucleic acids with small chemicals to selected neurons after a single intra-nasal application.

Chronos Therapeutics’ drug development scheme focuses in two main areas: - Repositioning FDA approved drugs. - Screening, discovery and development of novel proprietary drug candidates. Current Targets - Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia. - Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, ALS and Orphan Synucleopathies. Chronos Therapeutics’ research is successfully advancing from pre-clinical stages of development for age-related disease treatments to clinical development. Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan. Some of the most exciting and effective therapeutic approaches of the future will utilize our understanding of the biological programming of life-span and ageing that take place in every cell of our body. Harnessing this knowledge will lead to novel treatments for age related diseases such as Alzheimer's Disease, Diabetes, Cancer and Osteoporosis.

LikeMinds is a discovery service for identifying new stuff; including movies, books, music, people and places, with the help of other like-minded people. LikeMinds also allows users to share their ratings with friends by quickly copying their ratings from different websites including Netflix, Blockbuster, Amazon, Flixster, Yahoo, IMDB, RottenTomates , iTunes, Winamp, GoodReads, Shelfari and many more websites and applications. Then, users can begin to discover products and services enjoyed by other likeminded people.

Shanghai Guolian Stem Cell Technology Co., Ltd., established on 2009-12-17, Business scope includes stem cell biotechnology(Except for special items)technology development,technical consulting,Technical Services,technology transfer. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Hehong Biotechnology (Shanghai) Co., Ltd., established on 2006-02-27, Business scope includes biotechnology research and development,transfer of own technology,And provide relevant technical advice and technical services(involving administrative licensing,The operating permit).

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

PsyCheNomicS, Inc., part of Novasite Pharmaceuticals, Inc., is an American company. The firm develops therapeutic drug products. It was acquired by Novasite Pharmaceuticals, Inc. on June 15, 2005.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sunovion Pharmaceuticals Inc. (formerly Sepracor) engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders, and other illnesses. Its products include LUNESTA medicine that helps people sleep better; XOPENEX levalbuterol HCl inhalation solution; and BROVANA aformoterol tartrate inhalation solution. The company's products also comprise OMNARIS ciclesonide nasal spray; ALVESCO ciclesonide HFA inhalation aerosol; and LATUDA, an oral antipsychotic tablet for the treatment of schizophrenia. It offers products for the treatment of depression, epilepsy, neuropathic pain, and insomnia, as well as respiratory conditions, such as asthma, allergic rhinitis, and chronic obstructive pulmonary diseases.

Abbott Products SAS provides pharmaceutical products. The company is headquartered in Suresnes, France.

Abbott Healthcare Products BV, part of Abbott Laboratories, is a company headquartered in Weesp, the Netherlands, that manufactures and distributes pharmaceuticals.